Animal Pharm Podcast #13: Anizome sheds light on the burgeoning animal microbiome opportunity
In this latest Animal Pharm podcast, editor Joseph Harvey finds out how addressing the microbiome is changing the way the animal health industry approaches R&D. To understand the potential of microbiome products, he spoke to Oliver Hardcastle – the chief executive of new firm Anizome.
Anizome was established by academic and industry partners earlier this year. It claims to be the first company focused on a commercial therapeutic microbiome discovery platform dedicated to animal health and nutrition.
In the podcast above, Mr Hardcastle explains why fully understanding the animal microbiome is crucial for the veterinary medicines sector. He also tells Animal Pharm why start-ups – with a helping hand from investors – will hold the key to animal microbiome innovation.
The podcast also highlights a connection between the human microbiome sector, where a multitude of young businesses have already secured a wealth of funding, and trends that could occur in the animal microbiome space in the near future.
Anizome draws on expertise from Baylor College of Medicine, human microbiome company Diversigen and Stonehaven Incubate.
In an interview earlier this year, Mr Hardcastle told Animal Pharm: "The microbiome is a real gateway towards personalized nutrition and precision medicine for animals, while offering a very real opportunity to replace antibiotics with microbiome-based solutions, such as live biotherapeutic products."